CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. (Q55068564)
Jump to navigation
Jump to search
scientific article published on 20 January 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. |
scientific article published on 20 January 2015 |
Statements
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. (English)
1 reference
1 reference
1 reference
Xavier Pivot
1 reference
Alexey Manikhas
1 reference
Bogdan Żurawski
1 reference
Ewa Chmielowska
1 reference
Boguslawa Karaszewska
1 reference
Rozenn Allerton
1 reference
Paolo Bidoli
1 reference
Magdolna Dank
1 reference
Lajos Hornyak
1 reference
Sara Margolin
1 reference
Arnd Nusch
1 reference
Roma Parikh
1 reference
Fareha Nagi
1 reference
Michelle DeSilvio
1 reference
Sergio Santillana
1 reference
Ramona F Swaby
1 reference
Vladimir Semiglazov
1 reference
20 January 2015
1 reference
33
1 reference
14
1 reference
1564-1573
1 reference